Substituted nitrogen-containing heterocycles as vanilloid receptor ligands and their uses as medicament

Details for Australian Patent Application No. 2005299489 (hide)

Owner Amgen Inc.

Inventors Rzasa, Robert M.; Ognyanov, Vassil I.; Norman, Mark H.

Agent Wrays

Pub. Number AU-A-2005299489

PCT Pub. Number WO2006/047492

Priority 60/621,139 22.10.04 US

Filing date 21 October 2005

Wipo publication date 4 May 2006

International Classifications

C07D 405/04 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

A61K 31/506 (2006.01) - not condensed and containing further heterocyclic rings

A61P 29/00 (2006.01) Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents

C07D 403/04 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

Event Publications

19 April 2007 PCT application entered the National Phase

  PCT publication WO2006/047492 Priority application(s): WO2006/047492

1 July 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005299490-Taste-masked pharmaceutical compositions with gastrosoluble pore-formers

2005299482-Methods for lowering HIF-1 mediated gene expression